My Treatment Approach: Advancing Treatment Strategies for HER2+ Metastatic Breast Cancer - Episode 1
Clinical Scenario 1: A HER2+ mBC Patient With Trastuzumab Deruxtecan With Brain Mets
Panelists discuss how trastuzumab deruxtecan (Enhertu) is used to treat HER2-positive metastatic breast cancer with brain metastases, emphasizing its effectiveness in achieving systemic tumor reduction and CNS lesion stabilization while exploring treatment challenges and emerging strategies in this patient population.
Video content above is prompted by the following:
- Do you agree with the above treatment plan? What would you have done differently?
- What are your approaches to monitoring CNS disease?
- Could you provide an overview of the treatment landscape for HER2-positive advanced breast cancer with brain metastases (BMs)?
- Previous her pert , t_DM1 5 years ago 1st RP3 study in breast cancer to include patients with active brain mets. 50% of patients. 60% untreated.
- What challenges do you face in treating this patient population and what unmet needs remain?
Related Content:
